Log In
BCIQ
Print this Print this
 

KP511

  Manage Alerts
Collapse Summary General Information
Company KemPharm Inc.
DescriptionExtended-release oral prodrug of hydromorphone
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationPain
Indication DetailsTreat moderate to severe pain; Treat pain
Regulatory Designation U.S. - Fast Track (Treat moderate to severe pain)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today